What is it?
What Epitalon is
1Epitalon is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly (AEDG), also called Epithalon. Chemical identity does not establish the route, purity or clinical equivalence of a retail product.
Names, aliases and forms
Mechanisms of action
Telomerase result was a cell-culture finding
3A 2003 report examined telomerase activity and telomere length in cultured human somatic cells. It was not a trial of people taking Epitalon and cannot establish an anti-aging or cognitive outcome.
Gene-expression work remains preclinical
4A 2020 AEDG study discusses gene expression and protein synthesis during neurogenesis. This is hypothesis-generating preclinical research, not a human memory, focus, or mood result.
Potential effects and evidence map
Evidence for useful healthy-user outcomes remains predominantly preclinical. A small sublingual AEDG study measured blood-cell circadian genes rather than sleep or cognition; an older retinal-patient report does not establish a general benefit. Cell telomerase findings and studies of the different pineal extract Epithalamin cannot establish healthy-user longevity or cognitive effects.
Typical dosages and timing
A 2021 report studied this exposure for 20 days in middle-aged female night-shift workers. Of 75 participants, 40 with reduced melatonin-forming function were randomized to peptide or placebo. Blood-cell gene expression was measured, not sleep or cognition. It does not establish an injection dose or a consumer regimen.
Timing & effect horizon
The featured study window describes a single biomarker experiment. Reliable onset, The time for blood levels to fall by half during the final elimination phase.Source, duration of a useful effect and repeat-cycle schedules are not established; FDA found no pharmacokinetic data in its 2026 assessment.
Safety, side effects and risk profile
Human safety data are insufficient to estimate a numerical base risk; injection-related immune-response concerns remain explicit.
Clinical combination safety is not characterized; missing interaction data do not establish either compatibility or a particular interaction.
The reviewed material does not provide a pregnancy or lactation safety framework for Epitalon products; this is an evidence gap, not a demonstrated outcome.
Available human studies do not characterize adverse-event rates or long-term safety well enough for a numerical risk estimate. Unknown does not mean safe.
The U.S. FDA flags possible immunogenicity, meaning an unwanted immune response, from peptide aggregates and impurities in compounded Epitalon for certain routes. Its injection assessment emphasizes subcutaneous administration. Human frequency and severity are not established; a short biomarker study cannot rule out this hazard.
A 2015 analysis identified Epitalon in two preparations. That historical finding does not verify the identity, purity, storage, sterility, or route suitability of current listings.
FDA's 2026 assessment raises a theoretical concern that sustained telomerase activation could support cancerous cell growth. Limited animal studies cannot settle human carcinogenicity; this is an unresolved mechanistic concern, not a demonstrated human cancer rate.
Interactions and cautions
Clinical interaction studies have not established which medicines or other peptides can be combined with Epitalon safely. Missing data are not evidence of compatibility.
Legal and regulatory status
FDA's May 2026 assessment reported that neither Epitalon free base nor acetate was a component of an FDA-approved drug. That document evaluates U.S. drug compounding and is a staff assessment, not a final global legal determination. International sale and import status depends on jurisdiction and product category.
As of October 2026, the FDA page for the July 2026 Pharmacy Compounding Advisory Committee explains that committee recommendations are non-binding. Advisory consideration of a U.S. compounding ingredient does not establish approval of a marketed drug, food supplement or international product.
Practical buying and quality notes
- Epitalon, its acetate salt, N-acetyl derivatives and amidated derivatives are not interchangeable evidence labels. Check the full chemical identity on a product and its test report; a purity percentage alone does not establish equivalence.6
- A label specifying 10 mg per vial and five vials represents 50 mg per package. A ten-vial kit needs a separate total-mass calculation. Current rows include missing quantities and unreliable per-gram normalization: 0 mg or a zero unit price does not mean a free product. Package prices can be compared only after matching vial count, stated mass and currency; none gives a validated price per effective dose.
- The catalog groups the current vial offers as solution products. That category does not establish whether the supplied material is dry or reconstituted, nor verify concentration, identity, sterility, storage or route suitability. The merchant label and route-specific quality documentation remain necessary context.
FAQ
Can Epithalamin studies be applied to Epitalon?
6No direct transfer is justified. Epithalamin is a pineal-gland polypeptide extract; Epitalon is a defined synthetic tetrapeptide. Extract studies cannot establish the same outcomes for the isolated peptide.
Does Epitalon change telomerase?
3A cell-culture report found telomerase-related changes in human somatic cells. It does not show a healthy-human anti-aging, cognition, or lifespan benefit from a commercial product.
Does Epitalon improve memory or focus?
2No reliable healthy-human memory or focus benefit was established by the reviewed sources. Preclinical mechanism findings are not practical nootropic proof.
Can a vial label establish an Epitalon dose?
8No. Milligrams on a vial describe a product quantity. They do not show an effective or safe dose, an equivalent sublingual exposure or an injection regimen.
Is a ten-day course or repeated cycle evidence-based?
8A merchant course label does not establish treatment length or benefit. The reviewed human evidence does not validate a healthy-user repeat cycle or show how long any useful effect would last.
References
- PubChem. Epitalon (CID 219042). Accessed 2026-08-21.
- Overview of Epitalon - highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6):2691.
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592.
- Polyakova VO, et al. AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism. Molecules. 2020;25(3):609.
- Torre X, et al. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations. Drug Test Anal. 2015;7(3):259-264.
- U.S. Food and Drug Administration. Evaluation of Epitalon-Related Bulk Drug Substances. FDA briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee; assessment dated May 12, 2026.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: Epitalon. Accessed October 19, 2026.
- Khavinson V, Linkova N, Ivko O. AEDG Peptide Regulates the Expression of Circadian Genes Clock, Cry2, Csnk1e in Human Immune Cells. World Heart Journal. 2021;13(1):189-191.
- Khavinson V, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368.
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Accessed October 19, 2026.